Skip to main content

Table 1 Clinicopathologic characteristics of diffuse large B cell lymphoma patients

From: Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma

Variables

Full cohort (n = 51)

R-CHOP cohort (n = 43)

Number of cases (%)

Number of cases (%)

Age, years

 Mean (range)

59.6 (21–85)

 

  < 60

21 (41%)

17 (40%)

  ≥ 60

30 (59%)

26 (60%)

Sex

 Male

30 (59%)

24 (56%)

 Female

21 (41%)

19 (44%)

Primary site

 Nodal

18 (35%)

14 (33%)

 Extranodal

33 (65%)

29 (67%)

Ann Arbor stage

 I, II

27 (53%)

23 (54%)

 III, IV

24 (37%)

20 (46%)

IPI groupa

 Low (0–2)

30 (60%)

27 (63%)

 High (3–5)

20 (40%)

16 (37%)

B symptomsa

 Absent

31 (62%)

29 (67%)

 Present

19 (38%)

14 (33%)

ECOG PSa

 0, 1

40 (82%)

37 (86%)

 ≥ 2

9 (18%)

6 (14%)

LDHa

 Normal

21 (42%)

19 (44%)

 Elevated

29 (58%)

24 (56%)

BM involvementa

 Absent

42 (91%)

38 (93%)

 Present

4 (9%)

3 (7%)

Number of extranodal sitesa

 0, 1

40 (80%)

33 (77%)

 ≥ 2

10 (20%)

10 (23%)

EBER

 Negative

40 (78%)

36 (84%)

 Positive

11 (22%)

7 (16%)

Hans classification

 GCB

14 (27%)

12 (28%)

 Non-GCB

37 (73%)

31 (72%)

Treatment

 Rituximab + CHOP

43 (84%)

43 (100%)

 Rituximab + others

1 (2%)

0 (0%)

 Surgery only

2 (4%)

0 (0%)

 No Tx

5 (10%)

0 (0%)

  1. IPI international prognostic index, ECOG PS Eastern Cooperative Oncology Group Performance Status, LDH lactate dehydrogenase, BM bone marrow, EBER EBV-encoded RNA, GCB germinal center B-like, CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone
  2. aThese variables exclude missing values